Gabapentin Capsule
Product Images NDC 70518-3330

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-3330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 100mg 70518 3330 01)

Gabapentin 100 mg capsule label with a quantity of 1. The label includes the NDC number 70518-3330-01, repackaged by RemedyRepack Inc., Indiana, PA. Instructions advise to see the package insert for directions and to store the product between 20-25°C (68-77°F) with permitted excursions. Manufacturer noted as Ascend Labs, LLC, Montvale, NJ.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 100 mg capsules in a package labeled for 100 count. The label shows the NDC number as 70518-3330-00 and indicates the product is repackaged by RemedyRepack Inc. It includes basic storage instructions and a note to see the package insert for directions. The label also advises keeping the medication out of reach of children.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula depicting the calculation of creatinine clearance (CLCr) using patient age in years, weight in kilograms, serum creatinine in mg/dL, and a gender adjustment factor (0.85 for female patients). The equation is presented as text in a clinical or pharmacological context.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin showing a notable decrease in pain scores over time compared to placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

Line graph displaying mean pain scores over time in weeks, comparing placebo to Gabapentin at doses of 1800 mg/day and 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period, showing decreased pain scores for Gabapentin groups compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' displaying response rates for two studies. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin 3600 mg (GBP 3600). Study 2 presents 14% for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg. Statistical significance is noted with p-values below 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A chart comparing difference percentages against daily doses in milligrams for Gabapentin from three studies labeled a, b, and c. The x-axis shows daily doses at 600 mg, 900 mg, 1200 mg, and 1800 mg, while the y-axis represents percentage difference ranging from 2% to 22%. Each study is represented by distinct markers: black squares for Study a, gray squares for Study b, and white squares for Study c.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.